ReviewDrugs2023
Nadofaragene Firadenovec: First Approval.
Review in Drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 66 citations in OpenAlex.
- Comprehensive preclinical evaluation of second-generation miRNA-regulated Coxsackievirus B3-BHP: Potent antitumor efficacy and safety.Molecular therapy. Oncology · 2026Article
- ERAD-level gene switches for on-demand protein secretion and rapidly controlled gene therapies.Nature communications · 2026Article
- Article
- Review
- Broad-acting antivirals: the pursuit of pan-viral therapeutics in the era of pandemics.Journal of virology · 2026Review
- Oncolytic viruses and neoantigen vaccines: opportunities and challenges in priming antitumour immunity.The Lancet regional health. Europe · 2026Review
- Biopharmaceuticals for Cancer Treatment: An Update.Cancer medicine · 2026Review
- Consolidation enfortumab vedotin and pembrolizumab after cisplatin induction in metastatic urothelial cancer: Outcomes of complete response and bladder preservation.The Journal of international medical research · 2026Article
- Desmoglein 2 (DSG2)-knockout human respiratory epithelial cell model to study species B adenovirus receptor usage.Virologica Sinica · 2026Article
- Modern management of BCG-refractory non-muscle-invasive urothelial carcinoma of the urinary bladder.Urologie (Heidelberg, Germany) · 2026Review
- Immune checkpoint inhibitors in BCG-unresponsive non-muscle-invasive bladder cancer: a narrative review of evidence and future directions.Translational andrology and urology · 2026Review
- Type I-interferon β induces a strong anti-tumour response in bladder cancer cells.Journal of cancer research and clinical oncology · 2026Article
- Progress in the research and development of oncolytic virus therapies.Frontiers in pharmacology · 2026Review
- Oncobiotics in urinary bladder cancer. A narrative review of living cancer therapeutics.Frontiers in oncology · 2026Review
- Oncolytic Effects of S89K Matrix Protein of Vesicular Stomatitis Virus in Cervical Cancer.Advanced biomedical research · 2026Article
- Viral warriors: Unlocking the immune system's potential with oncolytic viruses in cancer immunotherapy.Molecular therapy. Oncology · 2025Review
- Pharmacotherapy for bladder spasm and irritative lower urinary tract symptoms associated with intravesical therapy for bladder cancer: a review of available evidence.Translational andrology and urology · 2025Review
- Nanotechnology and CRISPR/Cas-Mediated Gene Therapy Strategies: Potential Role for Treating Genetic Disorders.Molecular biotechnology · 2025Review
- Nanomedicines for the treatment of genitourinary neoplasms.Materials today. Bio · 2025Review
- Oncolytic Herpes Simplex Virus Therapy: Latest Advances, Core Challenges, and Future Outlook.Vaccines · 2025Review
Corrections and comments
- Erratum issued
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.